

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Tisagenlecleucel-T for treating relapsed or refractory
B-cell acute lymphoblastic leukaemia in people aged 3 to
25 years [ID1167]**

Final appraisal determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Yes.

Section 3.38 of the FAD states; “The committee noted a potential equality issue raised during the scoping process that blood support or haematopoietic stem cell transplant are not acceptable to some religious groups such as Jehovah's witnesses. These patients would normally instead have best supportive care. The committee agreed that if tisagenlecleucel does become an available treatment option, people can choose whether or not they wish to take it. Accordingly, this is not viewed as an equality issue.”

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No potential equality issues were identified during the appraisal process.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Tisagenlecleucel-T for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged 3 to 25 years [ID1167]

Issue date: November 2018

No potential equality issues were identified during the appraisal process.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, section 3.38 of the FAD.

Approved by Associate Director (name): ...Frances Sutcliffe.....

Date: 07/11/2018